Clinical responses to avelumab. (A) Time to and duration of response among patients with an objective response across treatment groups per investigator assessment. (B) Percentage change in tumor burden per investigator assessment. (C) Best percentage change in tumor burden per investigator assessment. (B-C) Only patients with the largest dominant masses at baseline and ≥1 postbaseline assessment are included. The last measurement prior to the randomization date served as the baseline measurement. Patients missing from this summary were included in the full analysis set but were excluded here due to missing data: no baseline measurements within the 28-day window (n = 2); no appropriate postbaseline measurements (n = 3). Q2W, every 2 weeks; Q3W, every 3 weeks.